



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:	)	Examiner: OHara, Eileen B.
	)	
Avi J. ASHKENAZI, et al.	)	Art Unit: 1646
	)	
Application Serial No.: 09/978,191	)	Confirmation No.: 4728
	)	
Filed: October 15, 2001	)	Attorney's Docket No.: 39780-2630 PIC4
	)	
For: <b>SECRETED AND</b>	)	<b>Customer No. 35489</b>
<b>TRANSMEMBRANE</b>	)	
<b>POLYPEPTIDES AND NUCLEIC</b>	)	
<b>ACIDS ENCODING THE SAME</b>	)	

EXPRESS MAIL LABEL NO. EL 977 608 874 US  
DATE MAILED: OCTOBER 4, 2004

RECEIVED

OCT 12 2004

TECH CENTER 2800

AMENDMENT AND RESPONSE TO OFFICE ACTION

**MAIL STOP AMENDMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Dear Sir:

In response to the Office Action mailed on June 2, 2004, in connection with the above-identified patent application (Paper No./Mail Date 05172004), please enter the following amendments, and consider the following arguments. This response is timely filed requesting a Petition for Extension of Time for one month with necessary fees.

Enclosed herewith are articles by (i) Orntoft *et al.*, (ii) Hyman *et al.*, (iii) Pollack *et al.*, and (iv) Hanna and Mornin, (v) a Declaration by Paul Polakis, Ph.D., (vi) a Declaration by Audrey Goddard, Ph.D, and (vii) a Declaration by Avi Ashkenazi, Ph.D.

Also filed herewith are a paper copy and the computer readable form of a revised Sequence Listing, as well as a Sequence Submission Statement. SEQ ID NO: 508 in the current Sequence Listing has been deleted to avoid the duplication.

Under 37 CFR §1.131, the present Amendment and Response is further accompanied by the submission of a Declaration that will be signed by all of the inventors, the consideration of which is respectfully requested. In addition, enclosed herewith is an Amendment Under

37 C.F.R. §1.48(b) to correct the inventorship in the present application, the consideration of which is respectfully requested.

**Amendments to the Specification** begin on page 3 of this paper.

**Amendments to the Claims** are reflected in the listing of claims that begins on page 12 of this paper.

**Remarks/Arguments** begin on page 16 of this paper.